Applied therapeutics reports second quarter 2023 financial results

Regulatory progress for govorestat (at-007) for the treatment of classic galactosemia, with potential nda submission based on discussions with the fda as well as ema marketing authorization application planned in fall 2023
APLT Ratings Summary
APLT Quant Ranking